Lung cancer
Conditions
Interventions
Modeling group:None
Test group: Obtain puncture tissue for organoid drug sensitivity test, and evaluate the consistency with clinical drug efficacy
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Subjects voluntarily joins the study and signs the informed consent form; 2) 18-75 years old; 3) Patients diagnosed as lung cancer (including NSCLC and small cell lung cancer. such as squamous cell carcinoma, adenocarcinoma and large cell lung cancer) by pathology with inoperable stage III or IV; 4) ECOG-PS score 0-2, patients who have no severe autoimmune diseases, severe complications and other contraindications to immunotherapy and can accept single or combined chemotherapy; 5) Enough samples for organoid culture; 6) Patients with imageable lesions. According to the evaluation criteria of solid tumor efficacy (RECIST 1.1), there is at least one single path measurable lesion.
Exclusion criteria
Exclusion criteria: 1) Other malignant diseases, serious autoimmune diseases or other immunotherapy contraindications that need systematic treatment; 2) Currently uncontrollable infections, the temperature >= 38 ?; 3) The ECOG score >= 3, and the expected survival period less than 6 months 4) Patients who are unable to obtain pathological tissues or whose organoid models have not been successfully constructed; 5) No clinically assessable lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of clinical efficacy of immunotherapy for solid tumor by iRECIST;Evaluation of organoid drug sensitivity testing; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytokine and lymphoid subgroup analysis;Genome, transcriptome, and immune microenvironment assessment; | — |
Countries
China
Contacts
Public ContactJiangyong Yu
Beijing Hospital
Outcome results
None listed